In the phase I clinical trial, including six transthyretin amyloidosis patients treated with NTLA-2001, the serum TTR protein concentration reduced by 52% on average in the group treated with 0.1 mg per kilogram and by 87% on average in the group treated with 0.3 mg per kilogram on day 28. This evidence concerns the gene TTR and prealbumin measurement.